Mycamine (Micafungin Sodium)

Micafungin, the active ingredient in Mycamine, is an echinocandin presented as an injection for intravenous use. It treats invasive candidiasis, esophageal candidiasis and candidemia in patients with compromised immune systems.

GNH USA supplies Mycamine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mycamine is an echinocandin antifungal indicated for serious systemic Candida infections.

- Invasive candidiasis: eradicates deep‑tissue Candida infections and reduces mortality. - Esophageal candidiasis: clears fungal lesions in the esophagus and relieves dysphagia. - Candidemia: eliminates Candida bloodstream infection and prevents metastatic spread.

Adverse reactions may occur with any intravenous antifungal therapy.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Elevated liver enzymes: transient increase in ALT/AST. - Rash: mild skin erythema. - Infusion‑related reactions: flushing or chills during administration.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Hypotension: sudden drop in blood pressure during infusion. - Anaphylaxis: severe allergic reaction with respiratory compromise. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal impairment: worsening kidney function in susceptible patients.

Safe use of Mycamine requires careful clinical monitoring.

- Liver function monitoring: check ALT/AST before and during therapy. - Renal assessment: evaluate creatinine clearance in patients with kidney disease. - Hypersensitivity evaluation: discontinue if signs of anaphylaxis appear. - Neonatal caution: use only when benefits outweigh risks in newborns. - Hepatic impairment adjustment: consider dose modification in severe liver disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin may interact with several co‑administered medicines.

Major Interactions (Avoid): - Cyclosporine: increased cyclosporine exposure may cause nephrotoxicity. - Rifampin: strong enzyme induction reduces micafungin plasma levels. - Concomitant use with other echinocandins: additive toxicity risk.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): potential for altered metabolism. - Warfarin: monitor INR as micafungin may affect anticoagulation. - Immunosuppressants (e.g., tacrolimus): observe for enhanced immunosuppression.